Background: Cytokines and cytokine antagonists modulate human immunodeficiency virus (HIV) replication in vitro and may be involved in HIV disease pathogenesis. An understanding of these cytokine networks may suggest novel treatment strategies for HIV-seropositive persons.
INTRODUCTION
Interleukin 1 a (IL-I a) and IL-1, are two distinct gene products that share a spectrum of inflammatory and immunological properties (1) . Both cytokines bind to the 80-kD type I IL-I receptor 668 Molecular Medicine, Volume 1, Number 6, September 1995 IL-IRI and IL-IRII, anti-IL-IRI antibody completely abrogates IL-I -induced activation of T669 protein kinase (8) . Anti-IL-IRI antibody also blocks IL-i-induced nuclear factor-KB (NF-KB) synthesis in B cells possessing only 10 IL-1RI per cell (9) . It has been shown that anti-IL-IRII antibody does not inhibit, but in fact enhances ILi-induced cytokine synthesis in IL-IRII-bearing cells (10, 11) .
Naturally occurring cytokine antagonists or soluble receptors can block the effects of certain cytokines. Interleukin 1 receptor antagonist (ILIRa) blocks IL-I activity both in vivo and in vitro (reviewed in Ref. 12) . Although it shares considerable sequence homology with IL-I a and IL-I f3, and binds to the IL-IRI and IL-IRII (13, 14) on various cells, it has no known agonist activity. In contrast to monoclonal antibodies to interleukin-I receptors, IL-IRa has been used in several clinical trials; it has been well tolerated and has not had any demonstrable agonist activity in humans (1) . Similarly, tumor necrosis factor (TNF) soluble receptors can block the effects of TNF. There are two soluble TNF receptors (sTNFRp55 and sTNFRp75; reviewed in Ref. 15) . In these studies, we used recombinant human TNF binding protein type 1 (rhTBP-1), a form of sTNFRp55, to block TNF agonist activity.
Studies performed in chronically HIV-i-infected promonocytic (Ul) and T lymphocytic cell lines have demonstrated that cytokines such as granulocyte-macrophage colonystimulating factor (16) , TNF (17) , , and interferon-y (19) enhance human immunodeficiency virus type 1 (HIV-1) expression. TNF appears to mediate its effect on HIV-1 by increasing the amount of free NF-KB that in turn binds to and stimulates the HIV-i-long terminal repeat (20) (21) (22) . IL-1 has also been shown to activate HIV-1 LTR expression (22, 23) and HIV-1 replication (24) , contrary to earlier reports (16) .
In this study, we investigated the effect of IL-I on HIV-1 expression and NF-KB DNA binding activity in U1 cells and examined the function of each IL-i R using specific monoclonal antibodies. Additional experiments were performed to evaluate the ability of interleukin 1 Phytohemagglutinin-Stimulated Peripheral Blood Mononuclear Cell Supernatants Peripheral blood mononuclear cells (PBMC) were obtained using ficoll-hypaque centrifugation as previously described (14) . Cells were then cultured at 2.5 X 106 cells/ml in RPMI supplemented with 10% FCS and 0.5 mg/ml phytohemagglutinin (PHA)-P (Sigma) at 37°C in a humidified atmosphere containing 5% CO2. After 24 hr, the cell suspension was centrifuged at 350 X g for 10 min. The supernatant was removed and frozen at -700C.
Ul Cell Line The U1 cell line is a subclone of HIV-1-infected U937 promonocytic cells (16) . Ul 24 hr at 370C, 5% CO2.
After incubation, cell viability was determined by trypan blue exclusion. Cultures were then mixed with Triton X-100 (0.5% final concentration; Du Pont/NEN Research Products, Boston, MA, U.S.A.) and frozen at -700C. Where indicated, cells were separated from the supernatant prior to the addition of Triton X. In these experiments, cell suspensions were centrifuged at 300 x g for 5 min; supernatants were removed, combined with Triton X, and frozen at -70°C. Cell pellets were washed once with RPMI, resuspended in 1000 ,ul RPMI with 10% FCS, mixed with Triton X-100, and then frozen at -70°C. Unseparated Ul cell suspensions, cells alone, and supernatants were assayed for p24 antigen by ELISA (Du Pont/NEN). IL-I a, IL-I 3, IL-IRa, and rhTBP-1 do not interfere with this ELISA (data not shown). The limit of detection of the ELISA was 12.5 pg/ml p24 antigen.
Electrophoretic Mobility Shift Assays NF-KB probe was isolated from a 93-bp HaeIII fragment from pHIVlacZ (NIAID AIDS Research and Reference Reagent Program) that was subsequently treated with alkaline phosphatase, then 5'-end labeled. Cellular and nuclear extracts were isolated according to the method by Dignam et al. (26) and Andrews and Faller (27) , respectively. Briefly, labeled NF-KB probe was incubated with 20 ,ug cellular extract or 10 ,ug nuclear extract and 1.5 jig poly (dI:dC) for 30 min at room temperature. The binding reaction contained 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, and 5% glycerol in a final volume of 25 pl (28). Bound and unbound fractions were separated on a 4% polyacrylamide gel with 50 mM Tris-HCl (pH 8.5), 380 mM glycine, and 2 mM EDTA (29) as the running buffer. Gels were dried and exposed to Kodak SB-5 X-ray film at -700C.
Receptor Binding Assay Using the methods of Spriggs et al. (5), Ul cells were suspended at 106 cells/ml in RPMI with 10% FCS and 5 ng/ml phorbol myristate acetate (PMA). After incubating for 24 hr at 37°C, dexamethasone (10-7 M final concentration) was added and the cells were incubated for an additional 14 hr. Subsequently, the cells were centrifuged at 300 X g for 10 min. The cell pellet was then resuspended for 15 
RESULTS

IL-1 Induces HIV-1 Expression in Ul Cells
In the present study, we investigated whether IL-1 could increase p24 antigen production in the chronically HIV-1-infected promonocytic Ul cell line. U1 cells were cultured with increasing concentrations of IL-1. In 11 experiments, IL-I induced a 2-to 7-fold increase in p24 antigen synthesis. Similar results were obtained using either IL-la or IL-I P. As illustrated in Fig. 1, IL-I induced a concentration-dependent increase in p24 antigen production (p < 0.001). The effective dose50 for IL-I was 1 ng/ml (p < 0.05). Maximal induction occurred at 10 ng/ml IL-1 (p < 0.001). IL-1 did not affect cell viability or proliferation at 50 ng/ml (data not shown).
IL-1 Increases Both Cell-Associated and Released HIV-1 Protein To ascertain if IL-I induced viral protein release, we measured the cell-associated and supernatant p24 antigen concentrations in unstimulated and IL-I -stimulated cultures (Fig. 2) . In unstimulated Ul cells, 58% of the p24 antigen was cell-associated (p = 0.01 when compared with supernatant p24 antigen). Cell-associated p24 antigen constituted 59% (p < 0.001) and 61% (p < 0.001) of IL-ia and IL-l,B-induced p24 antigen synthesis, respectively. Therefore, IL-1 increases both cell-associated and released HIV-1 p24. fected by incubation with 10 ,ug/ml IL-IRa (data not shown). As depicted in Fig. 3 , a 2-fold molar excess of IL-I Ra inhibited IL-I (3-induced p24 antigen production by 50% (p ' 0.001). At a 50-fold molar excess, IL-IRa completely suppressed IL-I,3-induced p24 antigen (p < 0.001).
IL-iRa Does Not Block PHA-Supernatant-, TNFa-, or PMA-Induced HIV-1 Expression PHA-supernatant (25% v/v) induced a 6-fold rise in p24 antigen synthesis. Constitutive p24 antigen synthesis was 50 10 pg/ml in this experiment. Ul cells stimulated with 10 ng/ml TNFa or 10 7 M PMA produced 5,100 + 300 pg/ml and 22,000 + 3,800 pg/ml p24 antigen, respectively. IL-I Ra, at a concentration of 10 ,ug/ml, did not inhibit PHA-supernatant-, TNFa-, or PMA-induced p24 antigen production (data not shown).
IL-1 Increases NF-cB DNA Binding Activity and IL-iRa Blocks This Effect
In order to determine whether the observed IL-1(3-induced HIV replication was NF-KB dependent, the electrophoretic mobility shift assay (EMSA) was employed to measure the level of transcriptionally active NF-KB in cells treated with IL-1,3 and IL-IRa. The results presented in Fig. 4 show that IL-1f3 (10 ng/ml) induced NF-KB levels approximately two-fold above the unstimulated control (Lanes 2 and 4). IL-1(3-induced NF-KB activity was decreased in the presence of 1 the IL-IRI mediated IL-1-induced increases of p24 antigen levels in Ul cells, these cells were preincubated with murine anti-human IL-I RI monoclonal antibody prior to stimulation with IL-I (3 (Fig. 5) . Antibody alone did not stimulate an increase in HIV-1 expression. However, anti-IL-1RI antibody inhibited IL-i-induced p24 antigen production in a concentration-dependent manner (p = 0.001). At a concentration of 5 ,g/ml, this antibody reduced p24 antigen synthesis by 42% (p = 0.05).
Antibody to the IL-IRII Blocks the Binding of IL-1 to Ul Cells, but Does Not Inhibit IL-1-Induced HIV-1 Expression Human monocytes can be induced to express large amounts of IL-IRII (5). We therefore examined whether anti-human IL-IRII monoclonal antibody could inhibit IL-1-induced p24 antigen production. As shown in Fig. 6, 2 often act synergistically (31), we investigated the effect of a combination of IL-1(3 and TNFa on p24 antigen synthesis. As depicted in Fig. 7A , Ul cells were treated with IL-13 (5 ng/ml) immediately prior to stimulation with increasing concentrations of TNFa. Cells stimulated with IL-1(3 alone synthesized 42 ± 5 pg/ml p24 antigen. At concentrations of exogenous TNFa equal to or greater than 10 ng/ml, IL-1(3 significantly enhanced TNFa-induced p24 antigen synthesis, giving approximately a 40% increase in p24 antigen expression at 100 ng/ml TNFa. Pretreatment for 24 hr with IL-1( also enhanced TNFainduced HIV-1 expression (Fig. 7B ). Cells cultured with IL-1l3 (5 ng/ml) and then stimulated for 24 hr with TNFa (10 ng/ml) contained 2.4-fold more p24 antigen than controls treated with TNFa alone (p < 0.01). Therefore, IL-1(3 enhances TNFa-induced HIV-1 expression when added before or simultaneously with TNFa. enously synthesized TNF to IL-1-induced p24 antigen production, U1 cells were incubated with 50 ng/ml IL-1 in the presence of rhTBP-1 (Fig. 8) . rhTBP-1 inhibited IL-la-and IL-i13-induced p24 antigen production by 27% (p < 0.001) and 24% (p = 0.001), respectively. clear factors (33) , stimulates transcription of proto-oncogenes (34) , and induces cytokine synthesis (35) . As reported here, IL-1 can also increase viral expression in the chronically HIV-1-infected promonocytic Ul cell line.
IL-i-
While there is well-established evidence that IL-I exerts its effects via the IL-i RI, recent studies suggest that the IL-I RII does not mediate signal transduction (10, 11) . Since U1 cells possess both the IL-IRI and the IL-IRII, we used these cells to investigate the different roles of the two IL-IRs. Our data demonstrate that even though monoclonal antibody directed against the IL-I RII blocked IL-I from binding to U 1 cells, this antibody did not affect IL-I-induced p24 antigen production. In contrast, monoclonal antibody to the IL-i RI inhibited IL-I-induced p24 antigen synthesis. The lack of complete inhibition by anti-IL-i RI may be due in part to induction of HIV-1 by IL-1 -induced TNF. Taken together, these findings demonstrate that the IL-IRII does not participate in signal transduction either alone or in cooperation with the IL-IRI in this experimental system. This is in agreement with recently published data by Poli et al. (24) .
By binding IL-I and therefore preventing its association with the IL-i RI, the IL-1RII might function as a downregulator of the immune response in conditions characterized by overproduction of IL-1. For example, during sepsis, neutrophils express an increased number of IL-1RII 673 (36) . Thus, the IL-IRII might act as a scavenger of excess IL-1. In contrast to other studies (24) , we were unable to demonstrate this phenomenon in our system despite proving that anti-IL-1RII blocked IL-1 binding to the receptor. One possible explanation for these differences is that the ratio of IL-I to IL-I receptors, which differed in these two studies, is an important factor. Whether there is already an increase in IL-IRII expression during asymptomatic HIV-1 infection is unknown. However, we do have evidence that plasma IL-IRa levels are elevated in both asymptomatic and symptomatic HIV-1 -seropositive patients as compared with healthy HIV-1 -seronegative controls (manuscript in preparation).
We found that IL-1 induces NF-KB DNA binding activity in Ul cells. IL-IRa blocks this effect, presumably because it prevents IL-I from binding to the type I receptor (9) . Several cytokines, including TNF, are known to increase HIV replication or HIV-LTR activity in association with NF-KB induction (20, 22) . Increased HIV expression and NF-KB activity occur during monocyte differentiation (37) and NF-KB activity is induced by HIV infection of monocytes (38) . Our finding that IL-I induces NF-KB activity in association with increased HIV replication is in agreement with these observations and with those of others who examined the effects of IL-I on HIV-LTR activity using a different assay system (22) . They stand in contrast to those of Poli et al. who used an experimental system with Ul cells that was similar to ours (24) . We speculate that this difference may relate to the concentrations of IL-I that were used (10 ng/ml in our experiments and 1 ng/ml in those of Poli et al.) , or other methodologic details that included cell number, time of culture, method of cell lysis and binding buffers.
Circulating TNFa levels are increased in AIDS patients (39, 40) . As demonstrated here, IL-1 enhances TNFa-induced HIV-1 expression. In addition, IL-1 induces TNFa (32) and this IL-i-induced TNFa contributes 27% of the total amount of IL-i-induced p24 antigen synthesis, as evidenced by blocking with rhTBP- 1. Previous studies have also demonstrated a role for endogenous TNFa in HIV-1 expression. Tadmori et al. (41) reported that anti-TNFa antibody suppressed both the constitutive expression of the HIV-1-long terminal repeat in Epstein-Barr virus-transformed B cells and expression induced by PMA in U937 cells. Anti-TNFa antibody has also been shown to suppress PMA-induced reverse transcriptase activity in U1 cells (42) . Using a chronically HIV-1-infected CD4+ promyelocytic clone, Butera et al. (43) found that the increase in reverse transcriptase activity induced by TNFa pulse treatment could be prevented by the subsequent addition of anti-TNFa monoclonal antibodies. Thalidomide, a selective inhibitor of TNFa synthesis, also inhibits granulocyte-macrophage colony-stimulating factor and IL-6-induced reverse transcriptase activity in Ul cells (44) .
While the magnitude of IL-I-induced HIV replication in vitro is less than that observed with TNF (approximately 10-fold less, data not shown), there may nonetheless be important in vivo effects of IL-1 on HIV disease progression. This may occur because of differential production of IL-I and TNF in vivo or differential expression of IL-I and TNF receptors or their naturally occurring antagonists under different conditions at different sites. Moreover, we have demonstrated potentially important enhancing effects of the concerted action of IL-I and TNF on HIV-1 replication and the induction of TNF by IL-I in this system. It may therefore be important to block the action of both these cytokines in future therapeutic interventions of cytokine networks in HIV-1 seropositive persons. In this regard, we have used specific cytokine antagonists that are well tolerated in human volunteers (reviewed in Refs. 1 and 45) , to block the effects of IL-1 in these experiments. IL-IRa almost completely blocked the effects of IL-I on HIV-1 replication and NF-KB DNA binding activity. rhTBP-1 partially blocked the effects of IL-I on HIV replication.
Our findings demonstrate that IL-1 induces HIV-1 expression in Ul cells via the IL-1RI and that this effect is mediated in part by TNF. IL-I also induces NF-KB DNA binding activity. IL-IRa blocks IL-1-induced effects on both HIV-1 replication and NF-KB activity. The intricate autocrine, paracrine, and juxtacrine effects of cytokines in HIV-1 -seropositive persons at various stages of disease are not fully known. It is possible that cytokine antagonists may be of benefit in the treatment of these patients to decrease HIV-1 replication at times when cytokine production is increased.
